Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026 8:30 AM EDTEdgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones
Transaction Creates Focused Cardiovascular Company with Enhanced Strategic ClarityÂ
Upfront Proceeds Expected to Fully Fund EDG-7500 Development Through Potential ApprovalÂ
On Track to Report 12-Week CIRRUS-HCM Part D Data in Q2 2026
BOULDER, Colo., June 1, 2026 /PRNewswire/ --Â Edgewise Therapeutics, Inc.... More
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
June 1, 2026 8:30 AM EDTAcquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion.
SURESNES, France, June 1, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it... More
